Skip to main content
SpringerLink
Log in

Sarcoma

  • Protocol
  • First Online:
Book cover Positron Emission Tomography

Part of the book series: Methods in Molecular Biology ((MIMB,volume 727))

Abstract

Sarcomas are a diverse group of malignancies originating in the connective tissue. The approach of a patient with a mass suspect for sarcoma starts with performing a biopsy to obtain tissue for evaluation by pathology. The main role of the current imaging modalities, in general, is to recognize patients with typically benign disease, in whom further invasive staging can be omitted, and select patients with a suspected malignancy, who should be referred for biopsy. Since soft tissue sarcoma tends to be large and heterogeneous, there is growing interest in using imaging modalities to guide these biopsies. Together with pathology, imaging modalities are the basis for accurate staging, evaluation of locoregional extent of the primary lesion, screening for occult metastases, evaluation of response to cancer treatment, and the detection of tumor recurrence. In this chapter, an overview is given of the use of 18F-FDG PET in these settings, its strengths as well as its limitations.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Source: http://seer.cancer.gov/csr/1975-2005/results_merged/sect_01_overview.pdf.

  2. Pisters, P.W., Leung, D.H., Woodruff, J., Shi, W., Brennan, M.F. (1996) Analysis of prognostic factors in 1041 patients with localized soft tissue sarcomas of the extremities J Clin Oncol 14, 1679–89.

    PubMed  CAS  Google Scholar 

  3. Fong, Y., Coit, D.G., Woodruff, J.M., Brennan, M.F. (1993) Lymph node metastases from soft tissue sarcoma in adults. Analysis of data from a prospective database of 1772 sarcoma patients. Ann Surg 217, 72–217.

    Article  PubMed  CAS  Google Scholar 

  4. Gaskeer, H.A., Albus-Lutter, C.E., Gortzak, E., Zoetmulder, F.A. (1988) Regional lymph node metastases in patients with soft tissue sarcomas of the extremities: what are the therapeutic consequences Eur J Surg Oncol 14, 151–6.

    Google Scholar 

  5. Greene, F.L., Page, D., Fleming, I., eds. (2002) AJCC Cancer Staging Manual, 6th ed. New York: Springer-Verlag.

    Google Scholar 

  6. Fadul, D., Fayad, L.M. (2008) Advanced modalities for the imaging of sarcoma Surg Clin North Ann 88, 521–37.

    Article  Google Scholar 

  7. Moulton, J.S., Blebea, J.S., Dunco, D.M., Braley, S.E., Biset, G.S., III, Emery, K.H. (1995) MR imaging of soft-tissue masses: diagnostic efficacy and value of distinguishing between benign and malignant lesions AJR Am J Roentgenol 164, 1191–9.

    PubMed  CAS  Google Scholar 

  8. De Schepper, A.M., De Bueckeleer, L., Vandevenne, J., Somville, J. (2000) Magnetic resonance imaging of soft tissue tumors Eur Radiol 10, 213–23.

    Article  PubMed  Google Scholar 

  9. Kransdorf, M.J., Murphey, M.D. (2000) Radiologic evaluation of soft-tissue masses: a current perspective AJR Am J Roentgenol 175, 575–87.

    PubMed  CAS  Google Scholar 

  10. van der Woude, H.J., Verstraete, K.L., Hogendoorn, P.C., Taminiau, A.H., Hermans, J., Bloem, J.L. (1998) Musculoskeletal tumors: does fast dynamic contrast-enhanced subtraction MR imagining contribute to the characterization Radiology 208, 821–8.

    PubMed  Google Scholar 

  11. Mayerhoefer, M.E., Breitenseher, M., Amann, G., Dominikus, M. (2008) Are signal intensity and homogeneity useful parameters for distinguishing between benign and malignant soft tissue masses on MR images? Objective evaluation by means of texture analysis Magn Reson Imaging 26(9), 1316–22.

    Article  PubMed  Google Scholar 

  12. Ioannidis, J.P., Lau, J. (2003) 18F-FDG PET for the diagnosis and grading of soft-tissue sarcoma: a meta-analysis J Nucl Med 44, 717–24.

    PubMed  Google Scholar 

  13. Lucas, J.D., O’Doherty, M.J., Cronin, B.F., et al. (1999) Prospective evaluation of soft-tissue masses and sarcomas using fluorodeoxyglucose positron emission tomography Br J Surg 86, 550–6.

    Article  PubMed  CAS  Google Scholar 

  14. Schulte, M., Brecht-Krauss, D., Heymer, B., et al. (1999) Fluorodeoxyglucose positron emission tomography of soft tissue tumours: is a non-invasive determination of biological activity possible Eur J Nucl Med 26, 599–605.

    Article  PubMed  CAS  Google Scholar 

  15. Lodge, M.A., Lucas, J.D., Marsden, P.K., Cronin, B.F., O’Doherty, M.J., Smith, M.A. (1999) A PET study of 18FDG uptake in soft tissue masses Eur J Nucl Med 26, 22–30.

    Article  PubMed  CAS  Google Scholar 

  16. Ferner, R.E., Lucas, J.D., O’Doherty, M.J, et al. (2000) Evaluation of (18)fluorodeoxyglucose positron emission tomography ((18)FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1 J Neurol Neurosurg Psychiatry 68, 353–7.

    Article  PubMed  CAS  Google Scholar 

  17. Folpe, A.L., Lyles, R.H., Sprouse, J.T., Conrad, E.U. III, Eary, J.F. (2000) (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma Clin Cancer Res 6, 1279–87.

    PubMed  CAS  Google Scholar 

  18. Eary, J.F., O’Sullivan, F., Powitan, Y., et al. (2002) Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis Eur J Nucl Med Mol Imaging 29, 1149–54.

    Article  PubMed  CAS  Google Scholar 

  19. Eary, J.F., O’Sullivan, F., O’Sullivan, J., Conrad, E.U. (2008) Spatial heterogeneity in sarcoma 18F-FDG uptake as predictor of patient outcome J Nucl Med 49, 1973–9.

    Article  PubMed  Google Scholar 

  20. Völker, T., Denecke, T., Steffen, I., et al. (2007) Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial J Clin Oncol 25, 5435–41.

    Article  PubMed  Google Scholar 

  21. Tateishi, U., Hosono, A., Makimoto, A., et al. (2007) Accuracy of 18F fluorodeoxyglucose positron emission tomography/computed tomography in staging of pediatric sarcomas J Pediatr Hematol Oncol 29, 608–12.

    Article  PubMed  Google Scholar 

  22. Tateishi, U., Yamaguchi, U., Seki, K., Terauchi, T., Arai, Y., Kim, E.E. (2007) Bone and soft-tissue sarcoma: perspective staging with fluorine 18 fluorodeoxyglucose PET/CT and conventional imaging Radiology 245, 839–47.

    Article  PubMed  Google Scholar 

  23. Dwamena, B.A., Sonnad, S.S., Angobaldo, J.O., Wahl, R.L. (1999) Metastases Fromm non-small cell lung cáncer: mediastinal staging in the 1990s – meta-analytic comparison of PET and CT Radiology 213, 530–6.

    PubMed  CAS  Google Scholar 

  24. Porter, G.A., Cantor, S.B., Ahmad, S.A., et al. (2002) Cost-effectiveness of staging computed tomography of the chest in patients with T2 soft tissue sarcomas Cancer 94, 197–204.

    Article  PubMed  Google Scholar 

  25. Delbeke, D., Martin, W.H., Sandler, M.P., Chapman, W.C., Wright, J.K. Jr., Pinson, C.W. (1998) Evaluation of benign vs. malignant hepatic lesions with positron emission tomography Arch Surg 133, 510–5.

    Article  PubMed  CAS  Google Scholar 

  26. Fong, Y., Saldinger, P.F., Akhurst, T., et al. (1999) Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases Ann J Surg 178, 282–7.

    Article  CAS  Google Scholar 

  27. Jager, P.L., Hoekstra, H.J., Leeuw, J., van Der Graaf, W.T., de Vries, E.G., Piers, R. (2000) Routine bone scintigraphy in primary staging of soft tissue sarcomas: is it worthwhile Cancer 89, 1726–31.

    Article  PubMed  CAS  Google Scholar 

  28. Stacchiotti, S., Collini, P., Messina, A., et al. (2009) High-grade soft-tissue sarcomas: tumor response assessment – pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria Radiology 251, 447–56.

    Article  PubMed  Google Scholar 

  29. Evilevitch, V., Weber, W.A., Tap, W.D. (2008) Reduction of glucose metabolic activity is more accurate than change in size in predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas Clin Cancer Res 14, 715–20.

    Article  PubMed  CAS  Google Scholar 

  30. Ceresoli, G.L., Chiti, A., Zucali, P.A., et al. (2007) Assessment of tumor response in malignant pleural mesothelioma. Cancer Treat Rev 33, 533–41.

    Article  PubMed  Google Scholar 

  31. Goffin, J., Baral, S., Tu, D., Nomikos, D., Seymour, L. (2005) Objective responses in patients with malignant melanoma or renal cell cancer in early clinical studies do not predict regulatory approval Clin Cancer Res 11, 5928–34.

    Article  PubMed  Google Scholar 

  32. Eisenhauer, E.A., Therasse, P., Bogaerts, J., et al. (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45, 228–47.

    Article  PubMed  CAS  Google Scholar 

  33. Juweid, M.E., Cheson, B.D. (2006) Positron emission tomography and assessment of cancer therapy N Engl J Med 354, 496–507.

    Article  PubMed  CAS  Google Scholar 

  34. Spaepen, K., Stroobants, S., Dupont, P., et al. (2001) Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first line chemotherapy in non-Hodgkin’s lymphoma: is [18F]FDG PET a valid alternative to conventional diagnostic methods J Clin Oncol 19, 414–9.

    PubMed  CAS  Google Scholar 

  35. Canellos, G.P. (1988) Residual mass in lymphoma may not be residual disease. J Clin Oncol 6, 931–3.

    PubMed  CAS  Google Scholar 

  36. Evilevitch, V., Weber, W.A., Tap, W.D., et al. (2008) Reduction of glucose metabolic activity is more accurate than change in size of predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas Clin Cancer Res 14, 715–20.

    Article  PubMed  CAS  Google Scholar 

  37. Scheutze, S.M., Rubin, B.P., Vernon, C., et al. (2005) Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy Cancer 103, 339–48.

    Article  Google Scholar 

  38. Schulte, M., Brecht-Krauss, D., Werner, M., et al. (1999) Evaluation of neoadjuvant therapy response of oseogenic sarcoma using FDG PET J Nucl Med 40, 1637–43.

    PubMed  CAS  Google Scholar 

  39. Franzius, C., Sciuk, J., Brinkschmidt, C., Jürgens, H., Schober, O. (2000) Evaluation of chemotherapy response in primary bone tumors with F-18 FDG positron emission tomography compared with histologically assessed tumor necrosis Clin Nucl Med 25, 874–81.

    Article  PubMed  CAS  Google Scholar 

  40. Ye, Z., Zhu, J., Tian, M., et al. (2008) Response of osteogenic sarcoma to neoadjuvant therapy: evaluated by 18F-FDG-PET Ann Nucl Med 22, 475–80.

    Article  PubMed  Google Scholar 

  41. Demetri, G.D., von Mehren, M., Blanke, C.D., et al. (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Eng J Med 347, 472–80.

    Article  CAS  Google Scholar 

  42. van Oosterom, A.T., Judson, I., Verweij, J., et al. (2001) European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Safety and efficacy of imatinib (ST1571) in metastatic gastrointestinal stromal tumors: a phase I study Lancet 358, 1421–3.

    Article  PubMed  Google Scholar 

  43. Blay, J.Y., Bonvalot, S., Casali, P., et al. (2005). GIST consensus meeting panelists Consensus meeting for the management of gastrointestinal stromal tumors Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO Ann Oncol 16, 566–78.

    Article  PubMed  Google Scholar 

  44. Van den Abbeele, A.D., Badawi, R.D. (2002) Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs) Eur J Cancer 38, S60–5.

    PubMed  Google Scholar 

  45. Stroobants, S., Goeminne, J., Seegers, M., et al. (2003) 18 FDG positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec) Eur J Cancer 39, 2012–20.

    Article  PubMed  CAS  Google Scholar 

  46. Antoch, G., Kanja, J., Bauer, S., et al. (2004) Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (ST1571) therapy in patients with gastrointestinal stromal tumors J Nucl Med 45, 357–65.

    PubMed  CAS  Google Scholar 

  47. Choi, H., Charnsangavej, C., Faria, S.C., et al. (2007) Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25, 1753–9.

    Article  PubMed  Google Scholar 

  48. Demetri, G.D., Benjamin, R.S., Blanke, C.D., et al. (2007) NCCN Task Force Report: management of patients with gastrointestinal stromal tumor (GIST) – update of the NCCN clinical practice guidelines J Natl Compr Canc Netw 5(2), S1–29.

    Google Scholar 

  49. Lewis, J.J., Leung, D., Casper, E.S., Woodruff, J., Hajdu, S.I., Brennan, M.F. (1999) Multifactorial analysis of long-term follow-up (more than 5 years) of primary extremity sarcoma Arch Surg 134, 190–4.

    Article  PubMed  CAS  Google Scholar 

  50. Pisters, P.W., Pollock, R.E., Lewis, V.O., et al. (2007) Long-term results of prospective trial of surgery alone with selective use of radiation for patients with T1 extremity and trunk soft tissue sarcomas Ann Surg 246, 675–81.

    Article  PubMed  Google Scholar 

  51. Stefanovski, P.D., Bidoli, E., De Paoli, A., et al. (2002) Prognostic factors in soft tissue sarcomas: a study of 395 patients Eur J Surg Oncol 28, 153–64.

    Article  PubMed  CAS  Google Scholar 

  52. Garner, H.W., Kransdorf, M.J., Bancroft, L.W., Peterson, J.J., Berquist, T.H., Murphey, M.D. (2009) Benign and malignant soft-tissue tumors: posttreatment MR imaging Radiographics 29, 119–34.

    Article  PubMed  Google Scholar 

  53. Vanel, D., Shapeero, L.G., Tardivon, A., Western, A., Guinebretiere, J.M. (1998) Dynamic contrast-enhanced MRI with subtraction of aggressive soft tissue tumors after resection Skeletal Radiol 27, 505–10.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Antwerp University Hospital, Edegem, Belgium

    Sarah Ceyssens & Sigrid Stroobants

Authors
  1. Sarah Ceyssens
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sigrid Stroobants
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sarah Ceyssens .

Editor information

Editors and Affiliations

  1. Dept. Radiology, University of Iowa, Hawkins Drive 200, Iowa City, 52242-1009, Iowa, USA

    Malik E. Juweid

  2. , Dept. Nuclear Medicine & PET Research, VU University Medical Centre, De Boelelaan 1117, Amsterdam, 1081 HV, Netherlands

    Otto S. Hoekstra

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Humana Press

About this protocol

Cite this protocol

Ceyssens, S., Stroobants, S. (2011). Sarcoma. In: Juweid, M., Hoekstra, O. (eds) Positron Emission Tomography. Methods in Molecular Biology, vol 727. Humana Press. https://doi.org/10.1007/978-1-61779-062-1_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-61779-062-1_11

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-61779-061-4

  • Online ISBN: 978-1-61779-062-1

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation